FY2025 · ended Dec 31, 2025 · Revenue $72.30M, +153.5% YoY · Filed Mar 19, 2026
Assembly Biosciences, Inc. (ASMB) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $72.3 million and a net loss of $6.1 million. Free cash flow was -$41.2 million. As of Jun 30, 2026 it held $320.4 million in cash and investments and $2.4 million in total debt.
Revenue (TTM)
$74.84M
+125.1% vs year-ago TTM
Net income (TTM)
$-42,000
+99.9% vs year-ago TTM
Operating cash flow (TTM)
$-38.48M
+31.1% vs year-ago TTM
Free cash flow (TTM)
$-38.57M
+30.9% vs year-ago TTM
EPS (TTM)
$-0.00
+100.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
15.86M
+111.4% vs prior year
Net cash
$318.01M
as of Jun 30, 2026
Operating margin
-11.8%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ASMB (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1426800
- Former names
- VENTRUS BIOSCIENCES INC (until Jul 11, 2014)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $72.3M | $28.5M | $7.2M | — | $6.3M |
| Operating income | -$12.1M | -$45.4M | -$64.6M | -$94.1M | -$132.7M |
| Net income | -$6.1M | -$40.2M | -$61.2M | -$93.1M | -$129.9M |
| Diluted EPS | -$0.55 | -$6.69 | -$13.38 | -$23.08 | — |
| Operating cash flow | -$41.1M | -$51.1M | $22.7M | -$84.5M | -$93.4M |
| Free cash flow | -$41.2M | -$51.1M | $22.5M | -$84.6M | -$96.5M |
| Total assets | $257.6M | $119.2M | $136.8M | $101.8M | $191.1M |
| Total liabilities | $50.8M | $85.8M | $95.7M | $19.1M | $22.1M |
| Stockholders' equity | $206.8M | $33.4M | $41.1M | $82.7M | $168.9M |
| Cash and investments | $248.1M | $112.1M | $130.2M | $91.6M | $174.6M |
| Total debt | $2.6M | $3.1M | $2.3M | $3.5M | $6.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K/A |
Amended current report
Results of operations
|
Aug 14, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Acquisition or sale of assets
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 5, 2026 | Jun 4, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
May 26, 2026 | May 21, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 22, 2026 | May 22, 2026 |
All 901 Assembly Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.